CXL Ophthalmics Publishes Results of EpiSmart® Cross-Linking Phase 2 Clinical Trial for Keratoconus in Cornea
Largest study to-date of corneal cross-linking to treat keratoconus Company aims to develop leading standard of care for keratoconus and corneal ectasia SHERBORN, Mass.–(BUSINESS WIRE)–CXL Ophthalmics, Inc., a clinical-stage company developing a minimally-invasive treatment for keratoconus, today published results of the EpiSmart cross-linking Phase 2 study for keratoconus in Cornea: The Journal of Cornea and … [Read more…]
